title: [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
abstract: The early assessment of benefits of newly approved drugs with novel active substances or new applications, which came into force on 1 January 2011 still represents a challenge to all parties involved. This article highlights the definitions, regulatory requirements and interaction between drug marketing approval and early assessment of benefits in Germany. The constellation of an extensively harmonized European and even international drug authorization process with a predominantly national regulation of drug reimbursement situation inevitably causes friction, which could be markedly reduced through early joint advisory discussions during the planning phase for pivotal clinical trials. During the year 2015 the Federal Institute for Drugs and Medical Devices (BfArM) carried out 300 scientific advice procedures of which 34 were concerned with applications in the field of indications for the central nervous system (CNS). In comparison 98 advisory meetings were held by the Federal Joint Committee (G-BA) of which the BfArM provided advice in 12 instances and in 2 cases on CNS indications. Study design, endpoints and appropriate comparative therapies are the key issues in exchanges and discussions between the BfArM, the G‑BA and applicants. Under these aspects the BfArM and G‑BA promote an early and consistent involvement in early advice procedures regarding the prerequisites for drug approval and assessment of additional benefits.
authors.affiliation: Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Deutschland. Leitung@bfarm.de.
authors.forename: K
authors.initials: K
authors.lastname: Broich
authors.affiliation: Gemeinsamer Bundesausschuss, Berlin, Deutschland.
authors.forename: W
authors.initials: W
authors.lastname: Löbker
authors.affiliation: Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Schulte
authors.affiliation: Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Beinlich
authors.affiliation: Gemeinsamer Bundesausschuss, Berlin, Deutschland.
authors.forename: T
authors.initials: T
authors.lastname: Müller
mesh_terms: D003362:Cost-Benefit Analysis / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D023381:Endpoint Determination / Q000379:methods; D005858:Germany; D033161:Government Regulation; D018166:Health Care Reform / Q000191:economics / Q000331:legislation & jurisprudence; D007880:Legislation, Drug; D008389:Marketing of Health Services / Q000191:economics / Q000331:legislation & jurisprudence*; D017063:Outcome Assessment, Health Care / Q000191:economics / Q000331:legislation & jurisprudence*; D011785:Quality Assurance, Health Care / Q000191:economics / Q000331:legislation & jurisprudence*
keywords: Act on the reform of the market for medicinal products (AMNOG); Additional Benefit analysis; Drug evaluation; Health technology assessment; Reimbursement